hepatology

NASH Fibrosis Peptide Therapy Reversal

In March 2024, the FDA approved resmetirom for NASH, marking the first regulatory victory after two decades of failed Phase 3 trials—yet NASH fibrosis progression and peptide therapy's potential role in reversing scarring remain largely unexplored in clinical settings.